Answers are grounded in this paper and cite their sources.
Background: Cyclin-dependent kinase 4 (CDK4) and CDK6 are central drivers of cell cycle progression in estrogen receptor-positive (ER+) breast cancer, and pharmacological inhibition of this pair has become a standard-of-care therapeutic strategy. However, currently approved CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib carry associated toxicities, including myelosuppression and other adverse effects which are associated with inhibition of CDK6 that limits tolerability and combinatorial strategies. Here we describe the preclinical characterization of ALK-13743, a novel, highly selective CDK4 inhibitor. Methods: ALK-13743 was synthesized and characterized biochemically for CDK4 selectivity. Anti-proliferative activity was assessed in wild-type (WT), RB1-deleted and CDK6-overexpressing isogenic ER+ breast cancer cell lines (MCF7, T47D) using live-cell fluorescence imaging. Impact on cell cycle progression was evaluated by immunoblotting. Combinatorial activity was assessed across a 307-drug library. In vivo efficacy was evaluated in T47D xenograft models. Results: ALK-13743 potently inhibited CDK4/Cyclin D1 with an IC50 of 33 nM and displayed selectivity over CDK6/Cyclin D3 (IC50, 99 nM), CDK2/Cyclin E1 (IC50, 1854 nM), and CDK1/Cyclin B1 (IC50, >10000 nM) in biochemical kinase assays. In cellular models, ALK-13743 demonstrated potent antiproliferative activity in CDK4-dependent ER+ breast cancer cells at nanomolar concentrations, while exhibiting limited inhibition in CDK6-dependent cell lines. ALK-13743 exhibited single-agent growth suppression and drug synergy with the selective estrogen receptor degrader giredestrant and PI3K pathway inhibitors but was entirely RB-dependent and blunted by CDK6 overexpression. Single-agent ALK-13743 treatment led to tumor regression in T47D xenografts in vivo. Conclusions: ALK-13743 is a potent, CDK4-selective inhibitor dependent upon RB for its antiproliferative profile in ER+ breast cancer models. Its favorable combinability with multiple clinically relevant targeted agents supports further development, particularly in combination regimens, and positions it as a differentiated CDK4-selective therapy for ER+ breast cancer.
No takes yet. Share an insight, caveat, or question.
Kumarasamy et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: